On January 14, Shenzhen YHLO Biotech Co., Ltd. released the 2022 annual performance forecast.

Healthcare and life science firms Pierian, Seven Bridges, and UgenTec have been acquired by investment fund Summa Equity for an undisclosed amount and merged to form a new precision medicine company, Velsera.

The US Food and Drug Administration recently granted Emergency Use Authorization for Scope Molecular Laboratory's SARS nCoV-2019 Multiplexed Assay for serial COVID-19 testing.

Agilent Technologies Inc. (NYSE: A) today announced it is investing approximately $725 million to double manufacturing capacity of therapeutic nucleic acids in response to rapid growth of the $1 billion market and strong demand for the company’s high-quality active pharmaceutical ingredients (API).

Bioantibody has completed its first round of financing totaling nearly 100 million yuan. This financing was led by Fang Fund and followed by New Industry Investment, Guoqian Venture Investment, Bondshine Capital. Phoenix Tree Capital acted as the exclusive financial advisor.

The US Food and Drug Administration said on Tuesday it has granted Emergency Use Authorization for DiaCarta's monkeypox PCR test.

Jiangsu Huadong Medical Device Industrial and Getein Biotech have signed an agreement to jointly manufacture and sell antigen test kits for Covid-19 and other in vitro diagnostics (IVD) products.

On January 9, Fosun Foundation, together with Fosun Pharma and Henan Genuine Biotech Co., Ltd., announced that they will donate 100 million yuan worth of oral drug Azvudine to rural areas in China.

Becton, Dickinson and Company (BD) and CerTest Biotec have announced that their molecular assay for detecting the Mpox virus has received Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA).

QIAGEN today announced it has completed the acquisition of Verogen, a leader in the use of next-generation sequencing (NGS) technologies to drive the future of human identification (HID) and forensic investigation.

On January 5, 2023, Guangzhou Darui Biotechnology Co., Ltd., the subsidiary of Daan Gene Co., Ltd., received China National Medical Products Administration (NMPA) class III medical device approval for its “Twenty Genetic Deafness Genes Mutation Detection Kit (Time of Flight Mass Spectrometry)”.

Genomic and diagnostic testing company Prenetics Global said Tuesday that the US Food and Drug Administration has cleared ACTOnco, a comprehensive genomic profiling test for solid tumors.

Foundation Medicine and Karyopharm Therapeutics said Tuesday they are collaborating on a companion diagnostic for Karyopharm's experimental drug Xpovio (selinexor), which is in development as a maintenance therapy for patients with advanced or recurrent TP53 wild-type endometrial cancer.

January 10, Suzhou Nanomicro Technology Co., Ltd. issued a voluntary disclosure announcement for its 2022 annual results forecast.

Foundation Medicine, Inc., a pioneer in molecular profiling for cancer, and Natera, Inc., a global leader in cell-free DNA testing, today launched an early access program for clinical use of FoundationOne®Tracker, a personalized circulating tumor DNA (ctDNA) monitoring assay.